Andere Sprachen Alvotech Nyse

Aktien

A3DK8U

LU2458332611

ALVO

Markt geschlossen - Nyse Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
14,15 ^USD	+3,66 %		+7,03 %	+50,85 %

25.04.	Cigna bietet Humira-Rivalen mit $0 Zuzahlung in Spezialapotheke an	RE
24.04.	Alvotech's Simponi Biosimilar Kandidat zeigt Wirksamkeit in Bestätigungsstudie	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

FDA Approval Of Alvotech/Teva Ustekinumab Biosimilar	26.04.
Cigna to offer Humira rivals with $0 copay at specialty pharmacy	25.04.
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi	25.04.
Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study	24.04.
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)	24.04.
Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi	24.04.
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira	22.04.
Sector Update: Health Care Stocks Advance Late Afternoon	19.04.
Sector Update: Health Care Stocks Rise Friday Afternoon	19.04.
Sector Update: Health Care	19.04.
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	19.04.
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	19.04.
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)	19.04.
Alvotech Signs U.S. Agreement to Expand Access for Newly Approved High-Concentration Interchangeable Biosimilar to Humira®	19.04.
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	17.04.
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis	16.04.
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	16.04.
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	16.04.
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment	16.04.
J&J beats first-quarter profit estimates on cancer drugs strength	16.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Alvotech Nyse

Aktien

A3DK8U

LU2458332611

ALVO

Andere Sprachen

Filter